Vidakovic Ivan, Kornmueller Karin, Fiedler Daniela, Khinast Johannes, Fröhlich Eleonore, Leitinger Gerd, Horn Christina, Quehenberger Julian, Spadiut Oliver, Prassl Ruth
Division of Medical Physics and Biophysics, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria.
Institute of Process and Particle Engineering, Graz University of Technology, 8010 Graz, Austria.
Pharmaceutics. 2024 May 23;16(6):694. doi: 10.3390/pharmaceutics16060694.
Archaeosomes were manufactured from natural archaeal lipids by a microfluidics-assisted single-step production method utilizing a mixture of di- and tetraether lipids extracted from The primary aim of this study was to investigate the exceptional stability of archaeosomes as potential carriers for oral drug delivery, with a focus on powdered formulations. The archaeosomes were negatively charged with a size of approximately 100 nm and a low polydispersity index. To assess their suitability for oral delivery, the archaeosomes were loaded with two model drugs: calcein, a fluorescent compound, and insulin, a peptide hormone. The archaeosomes demonstrated high stability in simulated intestinal fluids, with only 5% of the encapsulated compounds being released after 24 h, regardless of the presence of degrading enzymes or extremely acidic pH values such as those found in the stomach. In a co-culture cell model system mimicking the intestinal barrier, the archaeosomes showed strong adhesion to the cell membranes, facilitating a slow release of contents. The archaeosomes were loaded with insulin in a single-step procedure achieving an encapsulation efficiency of approximately 35%. These particles have been exposed to extreme manufacturing temperatures during freeze-drying and spray-drying processes, demonstrating remarkable resilience under these harsh conditions. The fabrication of stable dry powder formulations of archaeosomes represents a promising advancement toward the development of solid dosage forms for oral delivery of biological drugs.
古脂质体是通过微流控辅助单步生产方法,利用从[未提及来源]提取的二醚和四醚脂质混合物,由天然古细菌脂质制造而成。本研究的主要目的是研究古脂质体作为口服药物递送潜在载体的卓越稳定性,重点是粉末制剂。古脂质体带负电荷,大小约为100 nm,多分散指数低。为评估其口服递送的适用性,将两种模型药物载入古脂质体:荧光化合物钙黄绿素和肽激素胰岛素。古脂质体在模拟肠液中表现出高稳定性,24小时后仅有5%的包封化合物释放,无论是否存在降解酶或极端酸性pH值(如胃中的pH值)。在模拟肠屏障的共培养细胞模型系统中,古脂质体对细胞膜表现出强烈粘附性,促进内容物缓慢释放。通过单步程序将胰岛素载入古脂质体,包封效率约为35%。这些颗粒在冷冻干燥和喷雾干燥过程中经受了极端制造温度,在这些苛刻条件下表现出显著的复原力。稳定的古脂质体干粉制剂的制造代表了口服生物药物固体剂型开发方面的一项有前景的进展。